Board of Directors

Peter Bakema
Peter BakemaCEO, President, & Chairman of Board
Mr. Bakema has a forty year track record of successfully creating and developing businesses from the ground up. He has overseen multiple organizations with a human resource development of several hundred employees and contractors. His extensive background in business management, capitalization, mergers and acquisitions has been combined with years of hands on leadership experience in the medical device arena. This has given him the ability to adapt quickly to an ever changing healthcare sector. As the Chairman and CEO of CVR Global for the last ten years, Mr. Bakema is responsible for the direction of CVR Global with an emphasis on a sound business infrastructure that is capable of rapid scalability and regulatory compliance.
Wayne Hellman
Wayne HellmanVice Chairman & Board Director
Mr. Hellman’s career spans forty years having spent 16 years in various senior management roles with General Electric, culminating with the final four years reporting directly to Jack Welch (Chairman/CEO) where he led GE’s Venture Lighting Portfolio. In 1983, Mr. Hellman founded Advanced Lighting Technologies and served as its Chief Executive Officer until his retirement in 2014. Advanced Lighting Technologies, a Global Leader in Specialty Chemicals, Advanced Materials, Thin Film Coatings, Metal Halide Lighting and other Specialty Lighting Products launched with first year sales of $900,000. During his tenure, Mr. Hellman maintained consistent revenue growth and expanded global influence achieving Global revenue in excess of $250M. With manufacturing facilities and sales offices in 9 countries, employee headcount in excess of 1,000, completing 7 acquisitions and four international joint ventures in the Asian Pacific market, in 1995, Mr. Hellman led Advanced Lighting’s Initial Public Offering. In addition, he completed three secondary offerings totaling $200M, as well as completing a $100M high yield debt offering. Mr. Hellman took the Company Private in 2003 and prior to his retirement, in 2012 he led and completed an additional $170M High Yield Debt Offering.
Dallas Hack
Dallas HackBoard Director
Colonel Dallas Hack has led a decorated medical and military career. Prior to his service with the United States Army Medical Research and Materiel Command (USAMRMC), he developed a background in computer sciences and engineering, and served as Vice President for several biomedical companies. As a brain injury expert, he directed the Combat Casualty Care Research Program (CCCRP) at USAMRMC, where he was accountable for coordinating traumatic brain injury (TBI) research and technology across all Department of Defense groups. From 2008 to 2014, he oversaw projects that received over $2 billion in grant funding to advance TBI research and technology. His other appointments include Command Surgeon for the Multinational Force in Iraq and, up until his retirement in 2015, Senior Medical Advisor to the Principal Assistant, Research and Technology, USAMRMC.
Paul Blunden, M.D.
Paul Blunden, M.D.Board Director & Medical Advisor
Dr. Blunden is a board certified physician in obstetrics and gynecology with over twenty years in practice. Currently acting as the vice president and partner of a large multi-million dollar multi-provider practice servicing urban, suburban and rural patients. He has previously served as a department chairman for a major health system and has been a member of the executive leadership committee focused on fiscal management, quality improvement and recruiting. Mr. Blunden specializes in both Micro and Macro level managerial decision making with an emphasis on patient care and efficient business/medical coalescing.
James A. D'Orta
James A. D'OrtaBoard Director
James A. D’Orta, MD, is a seasoned business executive, entrepreneur, and physician, with many years of leadership experience in both clinical and business settings. Dr. D’Orta is known for his strategic insights and contributions on numerous boards of directors; his ability to position new and existing companies for long-term success; and his international network of senior-level contacts in business, government, and nonprofits. Dr. D’Orta also currently serves on the Board of Directors of Accuity Delivery Systems. Previously, he served as a Director of Cogentix Medical, also acting CEO of ACell and the Founder and CEO of Consumer Health Services, Inc., which provided medical support for the walk-in medical clinics in Duane Reed drugstores and was eventually acquired by Walgreens. He was also the founder and CEO of LifeLink MD, providing distribution, training and medical oversight for automated external defibrillators (AEDs), as well as public advocacy and education that helped make AEDs widely available.
Joel Kanter
Joel KanterBoard Director
Mr. Kanter has served as President of Windy City, Inc. a privately held investment firm since July 1986. He is a veteran healthcare venture capitalist whose family office has financially backed numerous medical device, life science and healthcare companies. Mr. Kanter has helped create billions in shareholder value, most notably; I-Flow which in 2009 was acquired by Kimberly-Clark for $324M, Clarisonic which in 2011 was acquired by L’Oréal for $525M, Prolor BioSciences which was acquired by OPKO Health in 2013 for USD $480M, Encore Medical which was acquired in 2006 by Blackstone for $860M, GranCare which in 1999 completed a $1.8B merger with Living Centers of America led by Apollo Management and Walnut Financial where he was Chief Executive Officer which was acquired in a transaction with Tower Hill Capital which resulted in an increase of $400M in shareholder value in 1999.Mr. Kanter currently serves on the Board of Directors of two public companies including Magna-Labs, Inc. and MEDITE Cancer Diagnostics, Inc. and also serves on the Boards of several private concerns. Mr. Kanter is also a Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, a former Trustee at the Georgetown Day School in Washington, D.C., and of the Union Institute & University.


The Reimbursement and Payer Committee:

The Reimbursement & Payor Committee will consist of Messrs. Joel Kanter, Dr. Paul Blunden and James D’Ortan, who will serve as the Chairman of the Reimbursement & Payor Committee. The Board has determined that all of the prospective members of the Reimbursement an Payor Committee are “independent,” as defined by NASDAQ listing standards. The responsibility of the Reimbursement and Payor  Committee is to review, set, draft and approve the reimbursement protocols with the government agencies and payors.  The Reimbursement & Payor Committee has also been appointed by the board.

Jim D’Orta (Chair)
Joel Kanter
Paul Blunden


The Development Plan Oversight Committee:

The Development Plan Oversight Committee will consist of Wayne Hellman and Colonel Dallas Hack M.D., who will serve as the Chairman of the Development Plan Oversight Committee. The Board has determined that all of the prospective members of the Development Plan Oversight Committee are “independent,” as defined by NASDAQ listing standards. The responsibility of the Development Plan Oversight Committee is to review, set, draft and approve the Development Plan between CVR Medical and CVR Global and to provide all oversight pertaining to milestones achieved against GAANT, payment and subsequent audit of all invoices received for services performed by CVR Global and to make any recommendations to the Board of Directors regarding any changes to the Development Plan needed.

Dallas Hack (Chair)
Wayne Hellman


The Audit Committee:

The Audit Committee will consist of Messrs. Wayne Hellman, Joel Kanter and James D’Orta . The board has determined that all of the prospective members of the Audit Committee are “independent,” as defined by the NASDAQ listing standards and by applicable SEC rules. In addition, the Board has determined that Mr. Kanter is an audit committee financial expert, and will serve as its Chairman as that term is defined by the SEC rules, by virtue of having the following attributes through relevant experience: (i) an understanding of generally accepted accounting principles and financial statements; (ii) the ability to assess the general application of such principles in connection with the accounting for estimates, accruals, and reserves; (iii) experience preparing, auditing, analyzing, or evaluating financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the Company’s financial statements, or experience actively supervising one or more persons engaged in such activities; (iv) an understanding of internal controls and procedures for financial reporting; and (v) an understanding of audit committee functions.  The function of the Audit Committee relates to oversight of the auditors, the auditing, accounting, and financial reporting processes, and the review of the Company’s financial reports and information. In addition, the functions of the Audit Committee will include, among other things, recommending to the board the engagement or discharge of independent auditors, discussing with the auditors their review of the Company’s quarterly results and the results of their audit, and reviewing the Company’s internal accounting controls.

Joel Kanter (Chair)
Wayne Hellman
Jim D’Orta


The Compensation Committee:

The Compensation Committee will consist of Messrs. Joel Kanter and Wayne Hellman, who will serve as the Chairman of the Compensation Committee. The Board has determined that all of the prospective members of the Compensation Committee are “independent,” as defined by NASDAQ listing standards. The responsibility of the Compensation Committee is to review and approve the compensation and other terms of employment of our Chief Executive Officer and our other executive officers, including all of the executive officers named in the Summary Compensation Table under the heading “Executive Compensation” below (the “Named Executive Officers”). Among its other duties, the Compensation Committee oversees all significant aspects of the Company’s compensation plans and benefit programs. The Compensation Committee annually reviews and approves corporate goals and objectives for the Chief Executive Officer’s compensation and evaluates the Chief Executive Officer’s performance in light of those goals and objectives. The Compensation Committee also recommends to the Board the compensation and benefits for members of the board. The Compensation Committee has also been appointed by the board to administer our Stock Option Plan. The Compensation Committee does not delegate any of its authority to other persons.

Wayne Hellman (Chair)
Joel Kanter


The Nominating & Corporate Governance Committee:

The Nominating and Corporate Governance Committee will be comprised of Dr. Colonel Hack, Dr. James D’Orta and Messrs. Wayne Hellman and Joel Kanter. The committee members are independent under applicable NASDAQ rules and regulations. The Nominating and Corporate Governance Committee is responsible for, among other things, considering potential board members, making recommendations to the full board as to nominees for election to the board, assessing the effectiveness of the board and implementing our corporate governance guidelines.

Code of Business Conduct and Ethics and Insider Trading Policy

Our board of directors will adopt a Code of Ethical Conduct and an Insider Trading Policy.

Wayne Hellman (Chair)
Jim D’Orta
Dallas Hack
Joel Kanter

Stay informed – Sign Up for Updates & News
Sign Up Here!

Click edit button to change this text.

Click edit button to change this text.